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Abstract
Background: Around half million new cases of cervical cancer arise each year, making the development of an effective 
therapeutic vaccine against HPV a high priority. As the E6 and E7 oncoproteins are expressed in all HPV-16 tumour cells, 
vaccines expressing these proteins might clear an already established tumour and support the treatment of HPV-
related precancerous lesions.
Methods: Three different immunisation regimens were tested in a pre-clinical trial in rabbits to evaluate the humoral 
and cell-mediated responses of a putative HPV-16 vaccine. Fowlpoxvirus (FP) recombinants separately expressing the 
HPV-16 E6 (FPE6) and E7 (FPE7) transgenes were used for priming, followed by E7 protein boosting.
Results: All of the protocols were effective in eliciting a high antibody response. This was also confirmed by 
interleukin-4 production, which increased after simultaneous priming with both FPE6 and FPE7 and after E7 protein 
boost. A cell-mediated immune response was also detected in most of the animals.
Conclusion: These results establish a preliminary profile for the therapy with the combined use of avipox 
recombinants, which may represent safer immunogens than vaccinia-based vectors in immuno-compromised 
individuals, as they express the transgenes in most mammalian cells in the absence of a productive replication.
Background
Infection by human papilloma viruses (HPVs) represents
the second most-common cause of malignancies in
women worldwide, and the oncogenic activity of the E6
and E7 early proteins expressed by the high-risk HPV-16
mucosal genotype accounts for the majority of anogenital
tumours [1]. E6 and E7 interfere with the host cell-cycle
regulatory proteins p53 and p105Rb, leading to transfor-
mation and carcinogenesis [2], facilitate cell immortalisa-
tion in primary human keratinocytes [3], increase
genomic instability [4], and maintain the transformed
phenotype [5] of cervical cancer cells [6].
Prophylactic vaccines are the best choice of interven-
tion against HPV, as they can inhibit infection and pre-
vent clinical disease by neutralising the incoming virus.
On this basis, capsid-L1-based virus-like-particles (VLPs)
have been successfully used to elicit HPV-11 neutralising
antibodies in a nude-mouse xenograft system [7], and the
recombinant L1/L2 proteins were able to prevent infec-
tion [8]. In particular, VLPs have proven to be successful
as prophylactic bivalent (Cervarix®, GSK) [9] and quadri-
valent (Gardasil®, Merck) [10] HPV vaccines in women, by
eliciting the production of virus-neutralising antibodies.
More recently, a recombinant adenovirus carrying the
HPV-16 L1 gene was shown to elicit complete protection
in Rhesus macaques [11]. However, the long delay in
tumour development after infection limits the assessment
of the vaccine efficacy [12] and suggests the need to sup-
port the treatment of HPV-related precancerous lesions
and tumours. Although extensive screening for early
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diagnosis has lead to a reduction in the mortality of
women in the developed countries, there are around
500,000 new cases of cervical cancer each year which
make the development of an effective therapeutic vaccine
highly desirable.
As they are expressed throughout the replicative cycle
of the virus, E6 and E7 might provide a target for thera-
peutic vaccines to clear an already established tumour.
They have been therefore evaluated in preclinical studies
for prophylaxis or therapy performing the challenge with
transformed cells after or before vaccination [13]. Immu-
notherapy with E6 and E7, either alone or expressed as
L2/E6/E7 fusion-protein by genetic DNA vaccines,
showed tumour growth control [14-16] and induced
HPV-specific cytotoxic T-lymphocytes (CTLs) targeted
to cancer cells [17-20]. However, peptides and purified
proteins, processed through the MHC class II, direct the
immune response towards the Th2 phenotype and gener-
ally fail to induce an adequate level of CD8+ T-cells and a
strong T-helper [21] response, so that a poor clinical effi-
cacy is often obtained [21].
Vaccinia virus (VV) recombinants expressing the HPV-
16 and HPV-18 E6 and E7 proteins have already been
used in several clinical studies for the immunotherapy of
cervical cancer [22-26]. Although many attempts were
performed also with VV attenuated strains, such as the
Modified Vaccinia Virus Ankara (MVA) [27,28], the repli-
cation of these viruses is only partially abortive [29], and
safety concerns were raised due to the severe side effects
of the vector in immuno-compromised subjects [30]. Avi-
pox viruses have been developed as novel vaccines
against human infectious diseases, as they are restricted
for replication to avian species [31], permissive for entry
and transgene expression in most mammalian cells, and
immunologically non cross-reactive with vaccinia. They
might represent therefore safer immunogens [32] which
have never been used as vectors for HPV and can be
administered to previously smallpox-experienced human
beings.
Due to papillomavirus species specificity, no natural
animal model is at present available to test human HPV
vaccines. The immune response in rodents inoculated
with E6- and E7-transfected cell lines has suggested their
use to test the immunotherapy of HPV-related tumours
[22]. Preclinical studies were successful in eliciting an
immune response in the bovine [33], canine [34], murine,
and cottontail rabbit papillomavirus (CRPV) models. In
particular, CRPV produces transient or progressive skin
warts in domestic rabbits, which can represent a simple
animal model both for prophylaxis and therapy [35-38],
when challenged with VX2T tumour rabbit cells [39].
In the present study, two new fowlpox recombinants
expressing the HPV-16 E6 and E7 oncogenes (FPE6 and
FPE7) were evaluated for the ability to elicit a complete
immune response and protection in rabbits following
prime-boost protocols where the two constructs were
given either alone or in combination. In these animals, we
also found that it is possible to evaluate a CTL response
by using syngeneic Ag-specific SV40-immortalized target
cells, and either expanded CTLs or fresh peripheral blood
mononuclear cells (PBMCs) as effector cells.
Methods
Cells
Specific-pathogen-free primary chick embryo fibroblasts
( C E F s )  w e r e  g r o w n  i n  D u l b e c c o ' s  M o d i f i e d  E a g l e ' s
Medium (DMEM) supplemented with 5% heat-inacti-
vated calf serum (CS; Gibco Life Technologies, Grand
Island, NY, USA), 5% Tryptose Phosphate Broth (Difco
Laboratories, Detroit, MI, USA), 100 U/ml penicillin and
100 mg/ml streptomycin (P/S). CaSki cells, containing
multiple copies of integrated HPV-16 DNA, and green
monkey kidney (Vero) cells were grown in DMEM sup-
plemented with 10% CS and P/S. Rabbit PBMCs were
obtained from heparinised rabbit blood and used for
CTLs and cytokine assays; the PBMCs were grown in
RPMI supplemented with glutamine, 10% FCS, and P/S.
Rabbit skin fibroblasts were obtained with a 3-mm biopsy
punch and immortalised with SV40 [40]; these were first
grown in DMEM supplemented with 10% CS, 5% FCS,
a n d  P / S ,  a n d  t h e n  t h e y  w e r e  u s e d  e i t h e r  w i t h  2 %
(DMEM2) or 10% (DMEM10) FCS in DMEM. Rabbit
VX2T cells, containing the complete CRPV genome [39],
k i n d l y  s u p p l i e d  b y  D r .  F .  B r e i t b u r d  ( P a s t e u r  I n s t i t u t e ,
Paris, France), were grown on collagene-plated type 1
flasks (Iwaki, Scitech Division, Asahi Techno Glass,
Tokyo, Japan) in DMEM supplemented with P/S, 5 μg/ml
amphotericin B (Sigma-Aldrich, St. Louis, MO), 40 μg/ml
gentamicin (Sigma), 6.5 ng/ml Epidermal Growth Factor
(EGF) (Sigma), 0.5 μg/ml hydrocortisone (Sigma) and 2
mM L-glutamine (Sigma).
Viruses
The FPE6  and FPE7  viruses were obtained by in vitro
homologous recombination [41], amplified on CEFs,
sucrose gradient purified, titred and used for animal
immunisation. The FP recombinant containing the env
gene of HIV-1 (FPenv) [42] was used as an irrelevant neg-
ative control in the CTL assay.
VX2T cells expansion and challenge with the minimal 
tumorigenic dose (MTD)
CD-1 nude mice (Charles River Lab., Calco, Italy), housed
and handled in sterile condition, were inoculated subcu-
taneously in the leg with 1 × 107 VX2T cells. When the
tumour reached around 1 cm3 volume (1 month), the ani-
mals were sacrificed, and the carcinomas explanted.
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free phosphate-buffered saline (PBS-) pH 7.2, propagated
again in CD-1 mice for a few cycles, until they were
expanded on collagen-coated flasks, stocked and used to
test the MTD for rabbit challenge. For the MTD test, two
rabbits were inoculated intradermally (i.d.) on the upper
back with a decreasing number of VX2T cells, starting
from 1.8 × 107 in 200 μl of PBS-. The MTD dose able to
generate a tumour in 6 days (107 cells) was used in 200 μl
volume to challenge all of the animals by a single intrad-
ermal injection.
The presence of E6 and E7 genes in VX2T cells was
assessed using CRPV primers V234 (5'-CTG-AGA-TCG-
CAA-CGC-ATT-GC-3') and V235 (5'-GCC-TGG-ATA-
TAA-TCC-AAG-TT-3') for E6 and V236 (5'-TAT-TTC-
TGC-TAT-CCT-GTG-CG-3') and V237 (5'-GCC-ATT-
TTC-AGT-TAC-AAC-AC-3') for E7. Amplifications were
carried out starting from 30 ng of DNA in a final volume
of 20 μl, in a mixture containing 1 μM of each primer, 200
μM of each dNTP, 2.5 μM MgCl2, 0.025 U/μl of Taq DNA
polymerase (Fermentas, MMedical, Milan). PCR condi-
tions were 95°C for 1 min followed by 30 cycles at 95°C
for 45 sec, 55°C for 30 sec, 72°C for 1 min, and 72°C for 7
min in the PTC-200 thermocycler (MJ Research,
Waltham, MA).
Production of the HPV-16 E6 and E7 proteins
Expression plasmids pQE30 (Qiagen, Valencia, CA, USA)
engineered to contain the E6 or E7 genes of HPV-16 [43]
were kindly supplied by Dr. Giorgi (Istituto Superiore di
Sanità, ISS, Rome, Italy), and called pQE30-E6/His and
pQE30-E7/His. After cloning into JM109 bacterial cells,
these were used for the production of the RGS His (H6)
E6 and E7 tagged proteins as per manufacturer instruc-
tions (Qiagen), with minor modifications, and referred to
as pE6 and pE7. Briefly, JM109/pQE30-E6/His bacterial
cells were lysed in Phosphate Lysis Buffer (PLB, 300 mM
NaCl, 1% Triton X-100, pH 8) in buffer A (10 mM Tris,
100 mM Na2HPO4, 6 M guanidine-HCl, pH 8). For
JM109/pQE30-E7/His, cell lysis was in PLB in buffer B
(10 mM Tris, 100 mM Na2HPO4, 8 M Urea, pH 8). After
clarification for 30 min at 17,000 × g at 4°C, the superna-
tants of the E6 and E7 preparations were supplemented
with 1% Triton X-100/20 mM imidazole pH 8 in buffer A
or B, respectively, before incubating with Ni-NTA aga-
rose resin (Qiagen) for 30 min at room temperature. After
washing once with 1% Triton X-100 in buffer A or B,
respectively, twice in buffer A or B, respectively, and mul-
tiple times with buffer C (100 mM Na2HPO4, 10 mM
Tris, 8 M Urea, pH 6.3) to a final OD280 of 0.013, the pro-
teins were eluted into different fractions with 1 M imida-
zole, pH 8. After separation by 15% SDS-PAGE, the
fractions enriched in the recombinant proteins were
pooled, quantified and stored at -80°C until use. The pro-
teins were used both for the immunisation and in the
ELISA assays. pE7 was dialysed overnight at 4°C using
slide-A-lyser cassettes (10 kDa MW cut-off, Pierce, Rock-
ford, IL) soaked in dialysis buffer (25 mM Tris-HCl, 100
mM NaCl).
Immunisation protocols
Four groups of two-month-old male New Zealand White
rabbits (Charles River) were inoculated with multiple
intradermal injections. Priming with the recombinant
viruses was performed five times, at 3-4-week intervals
(Fig. 1), with either FPE6 (Protocol 1, rabbits # 60, 61, 62,
63; 108 PFU/animal), or FPE7 (Protocol 2, rabbits # 72, 73,
74; 108 PFU/animal) or FPE6 plus FPE7 (Protocol 3, rabbits
# 80, 81, 82, 83; 108 PFU/each recombinant/animal) or
FPwt (Protocol 4, rabbits # 50, 51, 52, 53; 108 PFU/ani-
mal). The animals of Protocols 2 and 3 were also boosted
three times with the recombinant E7 protein (100 μg/
boost). Protein immunisations were performed in 50% v/
v Freund's incomplete adjuvant. All of the rabbits
remained in good health after all rounds of the immuni-
Figure 1 Prime-boost protocols for rabbit immunisation. Animals 
were immunised i.d. every month and bled before each inoculation. 
Four immunisation protocols were applied. In Protocol 1, the animals 
were immunised with the FPE6 recombinant (108 PFU/animal), in Proto-
col 2 with the FPE7 recombinant (108 PFU/animal), in Protocol 3 with 
the FPE6 + FPE7 recombinants (108 PFU/recombinant/animal), in Proto-
col 4 with FPwt (108 PFU/animal). In Protocols 2 and 3 the animals were 
also boosted with the recombinant E7 protein (100 μg/boost). Rabbits 
# 50, 62 and 83 died for natural reasons before the fifth priming. T1-T5, 
immunisation times for priming; P1-P4, immunisation times for protein 
boost.
Protocols Rabbit
# 60, 61, 62, 63
T0 T1 T2 T3 T4 T5
FPE6
1
# 72, 73, 74
T0 T1 T2 T3 T4 T5 P1 P2 P3 P4
FPE7 E7
2
# 80, 81, 82, 83
T0 T1 T2 T3 T4 T5 P1 P2 P3 P4
E7
3
FPE6 + FPE7
# 50, 51, 52, 53
T0 T1 T2 T3 T4 T5
FPwt
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sations. Rabbits # 50, 62 and 83 died before the fifth prim-
ing for natural reasons and do not appear in all of the
tests. Bleedings were performed before each immunisa-
tion, from the ear central artery using heparin (200 μl),
and are referred to as T1-T5 after priming immunisa-
tions, and as P1-P4 after the protein boosting. The
plasma fractions were aliquoted and frozen at -80°C, and
the PBMCs were used for the RNA extraction and CTL
assays.
All the animals were housed and handled in accordance
with the European guidelines no. 86/609/CEE and 116/92
for the protection of laboratory experimental animals and
laboratory animal care (Ministry of Health, Department
for Veterinary Public Health, Nutrition and Food Secu-
rity, Protocol 17/2006).
ELISA
The rabbit sera were immuno-adsorbed overnight at 4°C
with FPwt-infected Vero cells and tested for the presence
of antibodies against the HPV-16 E6 and E7 proteins
before the first and after each immunisation. The ELISA
was essentially performed as previously described [42].
Briefly, 96-well maxisorp microtitre plates (Nunc, Naper-
ville, IL, USA) were coated with either pE6 (250 ng/well)
in PBS- or pE7 (25 ng/well) in 0.05 M carbonate-bicar-
bonate buffer, pH 9.6, and incubated overnight at 4°C.
When CaSki lysates were used as a plate-bound immuno-
gen (105 cells/well in the coating buffer used for pE7),
after overnight incubation, the wells were masked with
the 1:1000-diluted AbE7/Gi or AbE6/Gi antibodies
(kindly supplied by Dr. Giorgi) for the E6 or E7 antibody
determination, respectively. A preliminary test was also
performed to find the appropriate serum dilution able to
saturate alternatively one of the two CaSki antigens, and
determine the relative contribution of each immunogen.
The sera of the E6- and E7-immunised rabbits were then
added at 1:25 or 1:250 dilutions, when proteins E6 or E7
were coated, or at 1:4000 dilution, when CaSki lysates
were plated.
The binding was revealed by a 1:1000 dilution of goat
anti-rabbit or goat anti-human horseradish-peroxidase-
conjugated sera (Dako-Cytomation, Glostrup, Denmark)
and tetramethylbenzidine (TMB) substrate (Sigma). The
pre-immune rabbit serum for each animal was used as a
negative control. The absorbance of each well was mea-
sured at 450 nm with a 550 Microplate Reader (Bio-Rad
Lab., Hercules, CA, USA).
RNA isolation and cytokine quantification
RNA extraction from PBMCs was performed at different
t i m e s  p o s t - i m m u n i s a t i o n  b y  T r i z o l  L S  ( G i b c o ) ,  a s  p e r
manufacturer instructions. The RNAs from all of the
samples were treated with 10 U RNase-free DNase I
(Roche Diagnostics, Indianapolis, IN, USA) for 4 h at
37°C to eliminate any cellular or viral DNA. The RNA
was then precipitated with 100% EtOH in the presence of
100 mM Na acetate, washed in 75% EtOH, and resus-
pended in diethylpyrocarbonate-treated water. Aliquots
of 100 ng (in duplicate) were used to reveal the levels of
expression of rabbit interferon (IFN)-γ and interleukin
(IL)-4 transcripts using the QuantiGene 2.0 Reagent Sys-
tem assay (Panomics, Fremont, CA, USA), according to
the manufacturer instructions. Rabbit β-actin (10 ng) was
used as a housekeeping gene transcript, to normalise the
cytokine quantification. Briefly, rabbit-specific probe sets
for IFN-γ (accession number DQ852341), IL-4 (accession
number DQ852343) and β-actin (accession number
AF309819) were incubated at 55°C with the RNAs from
samples at the different bleeding times, in a 96-well
mRNA capture plate. After overnight hybridization, the
samples were washed three times, supplemented with the
pre-amplifier reagent for 1 h at 55°C, and washed again.
The amplifier reagent was then added, and the samples
incubated for 1 h at 55°C; after further washing, this was
replaced by the label probe reagent for 1 h at 50°C. After
washing, the chemilumigenic 2.0 substrate was added for
5 min at room temperature, and then the luminescence of
e a c h  w e l l  w a s  r e a d  i n  a  l u m i n o m e t e r  ( M o d u l u s ™
Microplate Multimode Reader, Turner BioSystems,
Sunnyvale, CA). The IFN-γ and IL-4 values are expressed
as fold-differences versus  the baseline calculated from
non-stimulated pre-immune RNA of PBMCs, and norm-
alised against their β-actin expression.
Cytotoxic T-lymphocyte assays
CTL assays are often used to determine the ex-vivo spe-
cific cytolytic activity of CD8+ T lymphocytes. However,
rabbit PBMCs cannot be used as targets in this assay
because of their high spontaneous [51Cr] release. To over-
come this intrinsic difficulty, syngeneic cells were pre-
p a r e d  f r o m  s k i n  b i o p s i e s  o f  e a c h  r a b b i t ,  a s  p r e v i o u s l y
described [40], to be used instead of PBMCs, and SV40-
immortalised for their possible multiple use during these
experiments. The presence of both SV40 viral DNA and
RNA transcripts was confirmed by both PCR and RT-
PCR in each clone after RNA/DNA extraction from rab-
bit fibroblasts (data not shown), using the primers V230
(5'-CTT-TGG-AGG-CTT-CTG-GGA-TGC-AAC-T-3')
and V231 (5'-GCA-TGA-CTC-AAA-AAA-CTT-AGC-
AAT-TCT-G-3').
The target cells were confluent monolayers of SV40-
immortalised rabbit autologous skin cells (106 cells/5-cm
Petri dish) infected with 10 PFU/cell of the FPE6 or FPE7
recombinants. After an overnight incubation and wash-
ing in PBS-, the cells were dissociated with 0.2% EDTA in
PBS-, resuspended with 20 ml DMEM10, and pelleted by
centrifugation for 5 min at 400 × g. The cells were labelled
with 50 μCi [51Cr] in 100 μl DMEM2 for 2 h at 37°C,Radaelli et al. Journal of Translational Medicine 2010, 8:40
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washed with 20 ml DMEM10, and soaked in 20 ml
DMEM2 for 30 min. The cells were pelleted, resuspended
in RPMI with 10% FCS, plated (6 × 103/well) and the
effector cells were added.
Autologous effector rabbit PBMCs were used either as
freshly prepared or following Ag-stimulation and expan-
sion with IL-2 [40]. These were added to each well at the
effector-to-target-cell (E:T) ratios of 30:1 and 15:1. The
plates were centrifuged for 5 min at 250 × g, and the cells
were incubated at 37°C for 4 h. A volume of 50 μl super-
n a t a n t  w a s  t r a n s f e r r e d  f r o m  e a c h  w e l l  i n t o  a  9 6 - w e l l
LumaPlate containing a solid scintillator (PerkinElmer,
Boston, MA). The samples were dried overnight, and the
[51Cr] release was measured in a MicroBeta JET counter
(PerkinElmer). For each sample, the percentage of spe-
cific lysis was calculated by dividing the difference
between the mean counts per minute of experimental
and spontaneous release, by the difference between the
mean counts per minute of the total and spontaneous
release. For the total [51Cr] release, 100 μl 2% Triton X-
100 in RPMI was added before harvesting the 50 μl super-
natants. All of the assays were performed in triplicate and
repeated three to four times for each animal. The cells
infected with the FPenv recombinant [42] were used as an
irrelevant negative control.
Statistical analyses
Statistical analyses were performed using a one-way
ANOVA parametric test and Bonferroni/Newman-Keuls
analysis of variance using the GraphPad Prism software,
version 2.0, as well as the Student t-test. The statistical
significance was set as p < 0.05 (*), p < 0.01 (**), p < 0.001
(***).
Results
Specific antibody response is higher when CaSki lysates are 
plated
With the aim of developing a therapeutic vaccine for
HPV that can target cells expressing the E6 and E7 onco-
proteins, immunised animals were tested for the specific
antibody titres. Three groups of rabbits were primed five
times with the fowlpox recombinants, and FPE7 was fol-
lowed by three boosts with the corresponding protein
(Fig. 1). The humoral response against E6 or E7 was mea-
sured in the plasma at different times by ELISA, using
plates coated with either HPV-16 pE6 or pE7 proteins or
CaSki lysates (Fig. 2). Preimmune serum from each rabbit
was used as a negative control. As the rabbits are not syn-
geneic, results are shown for each single animal to evi-
dence the degree of variability among the animals and the
trend shown by each of them overtime. Also, to better
compare the E7 humoral response during prime and
boost immunisations when the immunogen was delivered
either alone (Protocol 2) or together with E6 (Protocol 3/
E7), values of the 1:250-diluted E7 sera were plotted on a
different scale than the 1:25-diluted E6 sera (Protocol 1
and 3/E6). This does not evidence the similar low
response during priming for FPE6 and FPE7, but clearly
shows the enhancement of the response when FPE7 is fol-
lowed by protein boost.
After priming, the rabbits of Protocol 1 and Protocol 3/
E6 (Fig. 2A) showed a modest increase of the antibody
levels against pE6, similar to that obtained against pE7
before boosting (Fig. 2B, T1-T5), considering the differ-
ent serum dilution (1:250 vs. 1:25). However, after the
protein boosting (P1-P4), the increase in the anti-E7 anti-
body titres was significant (Protocol 2, P4 vs. T1-T5, and
P4 vs. P1; ANOVA parametric test, p < 0.01). In particu-
lar, when the rabbits were primed with FPE6 + FPE7 (Fig.
2B, Protocol 3/E7), pE7 increased the antibody titres as
compared to primary immunisations (P1 vs. T1-T5, p <
0.05; P2-P4 vs. T1-T5 p < 0.001) and to the previous pro-
tein boosting (P2-P3 vs. P1, p < 0.05). The response to E7
also increased when the pE7 boosts were preceded by
FPE6 + FPE7 priming (Fig. 2B, Protocol 3/E7 vs. Protocol 2,
P1-P4, p < 0.01).
To exclude that sera were able to recognize only the E6
and E7 proteins given as a boosting antigen, plated CaSki
lysates were used as a source of native antigen. Overall,
the level of antibodies was much higher if compared to
the one obtained after plating the corresponding purified
proteins. Indeed, a significant increase of E6 (Protocol 3/
E6, T2-T5 vs. T1, p < 0.001) and E7 antibodies was pres-
ent after priming (Protocol 3/E7, T2-T3 and T4-T5 vs.
T1, p < 0.01 and p < 0.001) and boosting (Protocol 3/E7,
P3 vs. P1, P2, P4, p < 0.001; P1-P3 vs. T1-T5, p < 0.05).
The co-administration of FPE6 + FPE7 elicited a balanced 
Th1/Th2 cytokine response
Since the presence of antibodies does not necessarily cor-
relate with cytokine production, we tested the ability of
CD4-positive T cells to produce IFN-γ and IL-4 by mea-
suring the specific mRNAs using the QuantiGene 2.0
Reagent System assay. As for ELISA, the results from
each single animal were displayed to show the trend of
each rabbit overtime, which could be under-evaluated by
the degree of variability among non-syngeneic animals.
In all of the rabbits, the Th2 response was generally
higher than for Th1. In particular, in the FPE6-immunised
animals, IL-4 production was significantly higher than
IFN-γ (Fig. 3B, Protocol 1, Student t-test, p < 0.05). A sig-
nificant increase in IFN-γ production was noted when
the animals were immunised with FPE6 + FPE7 (Fig. 3A,
Protocol 3 vs. 2, p < 0.001) and when the E7 protein boost
followed the priming with both recombinant viruses (Fig.
3A, Protocol 3 vs. 2, p < 0.05). IFN-γ and IL-4 levels are
expressed as fold-differences vs. baseline, obtained fromRadaelli et al. Journal of Translational Medicine 2010, 8:40
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Figure 2 Analysis of the anti-E6 and anti-E7 humoral responses. Anti-E6 and anti-E7 antibody titres were determined by ELISA, after plating the 
E6 (Panel A) or E7 (Panel B) antigens. Heat-inactivated immuno-adsorbed sera were diluted 1:25 or 1:250 for protein-coated plates, and 1:4000 for 
plates coated with CaSki lysates. The reactions were revealed with goat anti-rabbit HRP-conjugated sera (1:1000) and TMB substrate. The rabbit pre-
immune serum from each animal was used as a negative control. Protein boosting with pE7 increased the anti-E7 antibody titres after priming with 
either FPE7 (Protocol 2) or with FPE6 + FPE7 (Protocol 3/E7). When CaSki lysates were used, the level of detected antibodies was much higher than after 
plating the purified proteins with a significant increase of E6 (Protocol 3/E6) and E7 antibodies after priming (Protocol 3/E7) and boosting (Protocol 
3/E7). Statistical significances using the ANOVA parametric test are shown: (*) p < 0.05; (**) p < 0.01; (***) p < 0.001.
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non-stimulated pre-immune PBMCs, and normalized
against β-actin expression.
Ex-vivo CTL activity was seen in all of the animals
The cytokine analysis only assesses the type of response
of antigen-specific cells, but does not directly demon-
strate their cytolytic function. [51Cr]-release assays were
therefore performed after the last immunisation (Fig. 4).
Overall, the results demonstrate that ex-vivo CTL activity
can be induced in most of the immunised rabbits.
C y t o l y t i c  T - c e l l s  s p e c i f i c  f o r  E 6  a n d  E 7  w e r e  d e t e c t e d
after Protocol 1 and 2, with a certain variability among
the animals, but they did not increase when the rabbits
were immunised with both FPE6 + FPE7 recombinants or
after boosting with the E7 protein (Protocols 3/E6 and 3/
E7). Rabbit # 81 was unresponsive to pE7 (Protocol 3/E7).
The results are shown as means of three to four assays,
which were performed on each animal with either fresh
Figure 3 Th1/Th2 cytokine determination by the QuantiGene 2.0 Reagent system. The RNAs of the different PBMC samples from all of the bleed-
ing times were used in duplicate to determine the levels of expression of the rabbit IFN-γ (Panel A) and IL-4 (Panel B) transcripts. In all of the animals, 
the Th2 response was generally higher than Th1 and, in particular, in FPE6-immunised animals of Protocol 1 IL-4 production was significantly higher 
than IFN-γ. IFN-γ production was significantly higher in Protocol 3 than in Protocol 2 both during priming and after the E7 protein boosting. IFN-γ and 
IL-4 levels are expressed as fold-differences vs. baseline, obtained from non-stimulated pre-immune PBMCs, and normalized against β-actin expres-
sion. Statistical significances using the Student t-test are shown: (*) p < 0.05; (**) p < 0.01; (***) p < 0.001.
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or in-vitro expanded PBMCs. Indeed, no significant dif-
ferences were seen between autologous effector rabbit
PBMCs either fresh or Ag-stimulated and expanded with
IL-2.
Challenge with VX2T cells showed tumour regression in all 
of the animals
In vitro propagated VX2T cells, analysed for the expres-
sion of the E6 (633 bp) and E7 gene (393 bp) transcripts,
were injected at different doses in naïve animals where
they developed solid tumours starting from 6 days post-
challenge. T umour size was measured every week with
callipers and the volume estimated by the formula width
× length × (width + length)/2. All of the animals showed a
growing tumour up to day 6 post challenge, but a similar
regression was seen thereafter in the rabbits vaccinated
either with the FPE6 and FPE7 recombinants or with the
FPwt empty vector (Fig. 5).
Discussion
Once sexually transmitted, no treatment is available that
can eradicate integrated HPV. Over the years, due to the
viral strategy of replication, which only occurs in termi-
nally differentiated epithelial cells, HPV vaccine develop-
ment has been hampered by the difficulty of growing the
virus in tissue cultures. VLP-based vaccines targeting the
major L1 viral capsid protein of high- and low-risk HPV-
types [44] proved effective in preventing persistent infec-
tion and precancerous lesions [45]. However, due to the
long delay between infection and the appearance of cervi-
cal intra-epithelial neoplasias, the long-term durability of
the protection by these vaccines has not yet been defined.
Although immunisation with VLPs has the potential to
reduce the incidence of cervical cancer [46] and current
pharmacological and surgical treatments can reduce or
eliminate neoplastic cells, new therapeutic strategies
need to be devised for already infected patients [45,47] to
prevent or delay disease recurrences. E6 and E7 oncopro-
teins, which are persistently expressed in HPV-trans-
formed cells [48], represent the main target for immune
therapy, as they maintain the proliferative state and pre-
vent apoptosis [49,50].
In the present study, we have described the complete
humoral and cellular immune responses that were elic-
ited in three groups of rabbits immunised either with
FPE6 alone or with FPE7 followed by the E7 protein boost.
We have demonstrated that: (i) high levels of anti-E6 and
anti-E7 antibodies were elicited; (ii) the boosting with the
E7 protein increased the humoral response after FPE7
priming; (iii) the coadministration of FPE6 + FPE7 induced
a balanced Th1/Th2 cytokine polarisation; and (iv) a spe-
cific CTL response was seen in all of the animals, using
autologous fibroblasts as targets.
Many vaccination trials have been performed on
patients with cervical cancer, genital warts or papillomas
[51,52], using the HPV-16 E6/E7 proteins and DNA or
viral vectors, carrying E6/E7 oncogenes but, in spite of
the immune response, the already compromised immune
system in these subjects often hampered the expected
efficacy. The use of viral vectors in a prime-boost regi-
men has already been shown to enhance the effectiveness
of vaccination and a high antibody level was seen to be
inversely correlated with disease progression [53,54]. In
this study, the antibody response detectable when either
the E6 or E7 proteins were plated was very low and did
not increase overtime, especially during priming. Co-
administration of FPE6 + FPE7 did not elicit a synergic
effect, but the anti-E7 response was significantly higher
when FPE6 + FPE7 priming was followed by the pE7 boost-
ing. Since no sequence homology exists between the E6
and E7 proteins, we can hypothesise a non-specific
immune stimulation by the doubling of the amount of the
FP vector used in Protocol 3. However, when plates were
coated with CaSki lysates instead of the E6 or E7 proteins
the antibody titre was much higher, which suggests the
recognition of conformational epitopes on native CaSki
proteins. Conversely, when plates were coated with dena-
tured E7, the high antibody level elicited only after boosts
can be ascribed to the recognition of epitopes displayed
by the same non-native protein used for immunisation.
Cytokine induction was mainly of the Th2 type, both
after the FPE6 and the FPE7 immunisations. The reduction
Figure 4 Functional virus-specific CTL responses. Effector rabbit 
PBMCs were used in triplicate, either freshly prepared or following Ag-
stimulation and expansion with IL-2. SV40-immortalised autologous 
target rabbit fibroblasts were labelled with [51Cr], and the cytotoxicity 
determined after the last immunisation. Non-stimulated and FPenv-
stimulated target fibroblasts were used as negative and irrelevant con-
trols. Cytolytic E6- and E7-specific T-cell activity were induced in most 
of the rabbits (Protocols 1 and 2; [E:T] ratio 30:1). Rabbit # 81 of Protocol 
3/E7 was unresponsive to pE7. The results are shown as means of three 
to four assays.
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of the antiviral cellular IFN-γ response has been
described for vaccinia and other poxviruses [55] that
express genes mimicking the IFN-γ receptor, but was not
found in FP-immunised rabbits [56]. In the present study,
IFN-γ showed a limited increase after both FPE6 or FPE7
immunisations, but a significant-one after priming with
both recombinants and the E7 protein boost which, given
the inability of FP to replicate in mammals, was probably
due to the double amount of fowlpox immunogens in
Protocol 3 and might explain the balanced Th1/Th2
response.
By eliciting CTLs against HPV-positive tumour cells,
therapeutic vaccination represents the most promising
treatment to reduce viral load and tumour growth in vivo
[17]. Many techniques can evaluate cellular immunity,
such as cytokine determinations by ELISpot, intracellular
staining, and microarrays, none of which are available for
the rabbit. As the conventional CTL assay is hampered in
these animals by the high spontaneous [51Cr]- release by
the PBMCs used as targets, we overcame these intrinsic
difficulties by using SV40-immortalized syngeneic skin
cells as targets and fresh PBMCs or expanded Ag-specific
CTLs as effector cells. CTLs were induced in all of the
rabbits, but the ex-vivo cytolytic activity specific for E6
and E7 did not increase when the animals were immu-
nised with FPE6 + FPE7 recombinants, nor after the E7
protein boost. We demonstrated, however, that the rabbit
model can be used to verify the presence of cellular
immune responses by using autologous fibroblasts. No
significant difference was seen between freshly prepared
or expanded PBMCs.
Immunisation with VV recombinants elicits a strong
immune response and has proven to be well tolerated in
animal and human trials. When expressing the E6 or E7
oncogenes, these recombinants have caused tumour
regression in patients with advanced cervical cancer and
the induction of CTLs specifically directed against
infected cells [18,22]. However, the use of VVs for small-
Figure 5 Tumour cell growth and regression. Rabbits were injected i.d. with a single dose of non-syngeneic VX2T tumour rabbit cells (107 cells in 
200 μl of PBS-), containing the complete genome of CRPV. Tumour size was measured every 6 days with callipers and the volume estimated by the 
formula width × length × (width + length)/2. The tumour sizes are given for each vaccinated and control (FPwt-injected) animals. All of the rabbits 
showed a tumour growth up to day 6 post challenge, which was followed by a regression, similar in rabbits vaccinated with the recombinant or FPwt 
viruses.
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pox vaccination causes lytic infection, ulcerations, and
scab formation, so that FP recombinants may represent
alternative safer immunogens due to their natural host-
range restriction to avian species [31,57], their correct
expression of transgenes in mammalian cells, and their
ability to elicit a complete immune response in vacci-
nated hosts [58].
Although previously published data described VX2T
cells tumorigenicity in New Zealand White rabbits [39],
after VX2T cells challenge we observed a complete
regression of the solid tumours not only in the rabbits
immunised with FPE6 and FPE7, but also in the animals
injected with FPwt. This can be explained by a failure in
the system, which, by using non-syngeneic VX2T cells,
may have triggered a complete regression as a conse-
quence of the different MHC-I expressed by the host vs.
the challenging cells.
Conclusion
The use of conformational epitopes, which can be recog-
nized only after plating CaSki cells, can significantly
increase the detectable antibody levels in the immunised
rabbits. FPE6 and FPE7 recombinants might induce CTLs
capable of destroying tumour cells and might represent
appropriate vectors to elicit anti-tumour immune
responses in humans. Further improvements of the
recombinants, using the E6 and E7 transgenes deleted of
the p53 and p105Rb cellular binding domain, might fur-
ther increase the safety of the vaccine. Recently, a p53
degradation-defective F47R mutant of HPV-16 E6 was
identified, which can restore the function of the p53 pro-
tein in HeLa cells [59] and can suppress their prolifera-
tion. Similarly, a genetically mutated non-transforming
E7 gene (E7GGG), which cannot bind to its p105Rb cellu-
lar substrate, could replace the oncogenic E7 counterpart
in new constructs and inhibit the E7-expressing TC-1 cell
t u m o u r  g r o w t h  i n  m i c e  [ 6 0 ] .  T h e s e  E 6  a n d  E 7  g e n e s ,
genetically modified and inserted into FPwt vectors, will
be evaluated for safety, immunogenicity and efficacy for
specific elimination of HPV-positive tumour cells.
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